Syed Mujtaba Hussain Naqvi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Syed Mujtaba Hussain Naqvi has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Akhilesh D Sharma
Dr Reddys Labs, Dept Med Affairs, Hyderabad, Telangana, India
1 shared publicationAmey Mane
Medical Affairs, Dr. Reddy’s Laboratories Pvt Ltd, Leelanagar, Hyderabad, India
1 shared publicationAmit Rauthan
Medical Oncology, Manipal Hospital, Bengaluru, IND
1 shared publicationArti Sanghavi
Medical Affairs, Dr. Reddy's Laboratories, Hyderabad, IND
1 shared publicationBhavesh P. Kotak
Medical Affairs, Dr. Reddy's Laboratories, Hyderabad, IND
1 shared publicationDevang Narayan Balraj
Department of Dermatology, Rajbal Skin Clinic, Bangalore, India
1 shared publication
Latest Publications
- Open Access
- 27 November 2025
- Published by Springer Nature in Cureus
- Vol. 17 (11) , e97914
Real-World Experience With Panitumumab or Bevacizumab as a First-Line Treatment for Metastatic Colorectal Cancer: An Indian Perspective
Objective This study aimed to evaluate the effectiveness and safety of panitumumab and bevacizumab in conjunction with first-line chemotherapy in Indian patients with metastatic colorectal cancer (mCRC). Materials and methods A retrospective chart review was performed involving consecutive patients treated between September 2015 and December 2023. Study endpoints included comparisons of the objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and adverse drug reactions associated with bevacizumab- and panitumumab-based regimens, along with assessments of the clinical profiles and tumor characteristics of patients with mCRC. Results This study analyzed data from 69 patients, including 30 in the panitumumab group and 39 in the bevacizumab group. The cohort consisted of 42 males (60.9%) and 27 females (39.1%), with a mean age of 54.0 ± 14.05 years. KRAS mutations were identified in 10.2% of patients. No significant differences were observed between the panitumumab and bevacizumab groups in ORR (70% vs. 69.23%, p=0.94), CBR (83.33% vs. 87.18%, p=0.65), or PFS (8.43 vs. 8.17 months, p=0.15). Median OS was 26.13 months in the bevacizumab group, while it was not reached in the panitumumab group at a median follow-up of 15.02 months. Adverse events were more frequent in the bevacizumab group. Additionally, no significant differences in clinical outcomes were found between bevacizumab- and panitumumab-based regimens for tumors originating on either the left or right side. Conclusions The results of the study show that bevacizumab and panitumumab-based regimens provide comparable outcomes in Indian patients with mCRC.
- 27 November 2025
- Published by Springer Nature in Cureus
- Vol. 17 (11) , e97914
Open AccessReal-World Experience With Panitumumab or Bevacizumab as a First-Line Treatment for Metastatic Colorectal Cancer: An Indian Perspective
Objective This study aimed to evaluate the effectiveness and safety of panitumumab and bevacizumab in conjunction with first-line chemotherapy in Indian patients with metastatic colorectal cancer (mCRC). Materials and methods A retrospective chart review was performed involving consecutive patients treated between September 2015 and December 2023. Study endpoints included comparisons of the objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and adverse drug reactions associated with bevacizumab- and panitumumab-based regimens, along with assessments of the clinical profiles and tumor characteristics of patients with mCRC. Results This study analyzed data from 69 patients, including 30 in the panitumumab group and 39 in the bevacizumab group. The cohort consisted of 42 males (60.9%) and 27 females (39.1%), with a mean age of 54.0 ± 14.05 years. KRAS mutations were identified in 10.2% of patients. No significant differences were observed between the panitumumab and bevacizumab groups in ORR (70% vs. 69.23%, p=0.94), CBR (83.33% vs. 87.18%, p=0.65), or PFS (8.43 vs. 8.17 months, p=0.15). Median OS was 26.13 months in the bevacizumab group, while it was not reached in the panitumumab group at a median follow-up of 15.02 months. Adverse events were more frequent in the bevacizumab group. Additionally, no significant differences in clinical outcomes were found between bevacizumab- and panitumumab-based regimens for tumors originating on either the left or right side. Conclusions The results of the study show that bevacizumab and panitumumab-based regimens provide comparable outcomes in Indian patients with mCRC.
- Open Access
- 28 August 2021
- Published by Springer Nature in Dermatology and Therapy
- Vol. 11 (5) , 1717-1732
Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study
Introduction Clobetasol propionate (0.05% standard dose formulation), a topical corticosteroid, leads to systemic side-effects like hypothalamic–pituitary–adrenal (HPA) axis suppression at doses as low as 2 g/day. The aim of this study was to evaluate HPA axis suppression, efficacy, and safety of clobetasol propionate (0.025%, formulation 5 and 13) versus currently marketed 0.05% cream in Indian patients with moderate-to-severe psoriasis. Methods In this phase 2a investigator-blinded study, patients aged ≥ 18 years with moderate-to-severe psoriasis were randomized 1:1:1 to receive clobetasol propionate 0.025% formulation 5, or 13, or 0.05% cream; twice daily for 28 days. Safety endpoints included adrenocorticotropic hormone (ACTH) test results at day 28 (primary), and local tolerability at each visit (burning/stinging/pruritus, secondary). Efficacy endpoints included Psoriasis Global Assessment (PGA) score. Results Overall, 88 patients received clobetasol propionate 0.025% formulation 5 and 13 (n = 29 for both) and 0.05% cream (n = 30). At day 28, the proportion of patients with an abnormal ACTH stimulation test (cortisol levels ≤ 18 µg/dl) was numerically lower in 0.025% formulations: 5 (20.7%) and 13 (17.2%) compared with 0.05% cream (30.0%), (p = 0.320). Decrease in burning/stinging /pruritus scores were comparable in all treatment groups and PGA success rates were higher with 0.025% formulations: 5 (38.9%) and 13 (36.8%) compared with 0.05% cream (30.8%). Conclusion Clobetasol propionate 0.025% could be an effective treatment for moderate-to-severe psoriasis compared with 0.05% cream, demonstrating comparable efficacy with a better systemic safety profile. Trial Registration Number REF/2018/01/016779.
- 28 August 2021
- Published by Springer Nature in Dermatology and Therapy
- Vol. 11 (5) , 1717-1732
Open AccessEfficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study
Introduction Clobetasol propionate (0.05% standard dose formulation), a topical corticosteroid, leads to systemic side-effects like hypothalamic–pituitary–adrenal (HPA) axis suppression at doses as low as 2 g/day. The aim of this study was to evaluate HPA axis suppression, efficacy, and safety of clobetasol propionate (0.025%, formulation 5 and 13) versus currently marketed 0.05% cream in Indian patients with moderate-to-severe psoriasis. Methods In this phase 2a investigator-blinded study, patients aged ≥ 18 years with moderate-to-severe psoriasis were randomized 1:1:1 to receive clobetasol propionate 0.025% formulation 5, or 13, or 0.05% cream; twice daily for 28 days. Safety endpoints included adrenocorticotropic hormone (ACTH) test results at day 28 (primary), and local tolerability at each visit (burning/stinging/pruritus, secondary). Efficacy endpoints included Psoriasis Global Assessment (PGA) score. Results Overall, 88 patients received clobetasol propionate 0.025% formulation 5 and 13 (n = 29 for both) and 0.05% cream (n = 30). At day 28, the proportion of patients with an abnormal ACTH stimulation test (cortisol levels ≤ 18 µg/dl) was numerically lower in 0.025% formulations: 5 (20.7%) and 13 (17.2%) compared with 0.05% cream (30.0%), (p = 0.320). Decrease in burning/stinging /pruritus scores were comparable in all treatment groups and PGA success rates were higher with 0.025% formulations: 5 (38.9%) and 13 (36.8%) compared with 0.05% cream (30.8%). Conclusion Clobetasol propionate 0.025% could be an effective treatment for moderate-to-severe psoriasis compared with 0.05% cream, demonstrating comparable efficacy with a better systemic safety profile. Trial Registration Number REF/2018/01/016779.
- Open Access
- 1 March 2018
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 12 (3) , FE01-FE03
Novel Methods and Regulation on Electronic Data Collection in Clinical Trials
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
- 1 March 2018
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 12 (3) , FE01-FE03
Open AccessNovel Methods and Regulation on Electronic Data Collection in Clinical Trials
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.